Reviews/TNF Alpha Inhibitors/TNF-alpha inhibitors combined with methotrexate are superior to methotrexate monotherapy in RA
· TN-RA-02 · v2
Two head-to-head randomised trials in people with early rheumatoid arthritis compared adalimumab plus methotrexate against methotrexate alone, and both favoured the combination [9][5]. In OPTIMA, more patients on the combination reached good clinical, functional and joint-protection outcomes at six months [9], and in PREMIER the combination improved physical function and quality of life over two years [5]. Two further papers add supporting context: one benchmarks the combination against methotrexate-plus-placebo [6] and one shows the combination holds up over four years [4]. The main caution is that every qualifying study tested only one drug, adalimumab, even though the claim is about the whole TNF-inhibitor class. A second caution is that OPTIMA found starting methotrexate first and adding the TNF inhibitor later gave similar longer-term clinical results, with only the joint-protection benefit clearly persisting [9].
Two direct RCTs in early RA favour adalimumab plus methotrexate over methotrexate monotherapy. OPTIMA [9] reports significantly greater good clinical (53% vs 30%), functional (45% vs 33%) and radiographic (87% vs 72%) outcomes at week 26 for adalimumab+MTX (n=466) versus MTX monotherapy (n=460). PREMIER [5] shows significant baseline-to-week-104 improvements across HAQ-DI, SF-36 components, SF-6D, VAS pain and global, FACIT-F and HUI-3 for adalimumab+MTX versus MTX monotherapy. SELECT-COMPARE [6] places adalimumab+MTX against placebo+MTX, and ARMADA [4] shows adalimumab+MTX sustained clinical response and remission to 4 years. All four included papers test adalimumab only. The contested point: The evidence divides on how durable and how general the superiority is. OPTIMA [9] shows that adding the TNF inhibitor at week 26 yields similar longer-term clinical and functional outcomes, with only radiographic benefit persisting, so the clinical edge of upfront combination is largely early. The whole included corpus is adalimumab-based [4][5][6][9], leaving the class-level 'TNFi' step inferred rather than shown.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from TNF Alpha Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Every included paper tests adalimumab; the corpus holds no RCT of etanercept, infliximab, golimumab or certolizumab versus MTX monotherapy in RA, so the class-level 'TNFi' claim is inferred from a single molecule.
OPTIMA [9] shows that delaying TNFi to week 26 yields similar long-term clinical results, so the clinical advantage of upfront combination is largely early; only the radiographic benefit persists, tempering an unqualified 'superior'.
Where it remains uncertain. Every qualifying study tests adalimumab only [4][5][6][9], and OPTIMA [9] finds delayed TNFi addition gives similar longer-term clinical results, leaving radiographic benefit as the durable advantage.
Aleatory
Effect magnitudes come from finite early-RA samples ([9] n=466 vs 460; [5] n=799), so point estimates carry sampling noise.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes a placebo+MTX-controlled foundation and durability of adalimumab+MTX response to 4 years.
“Patients responding inadequately to MTX were entered into a 24 week, controlled study (ARMADA) with adalimumab plus MTX or placebo plus MTX, and some were enrolled in a subsequent open label extension.”
Panel auditInternal validity: medium · scope of inference: Longstanding active RA responding inadequately to MTX, long-term maintenance on adalimumab+MTX.Key limitations: open-label extension · no comparative contrast reported · responder-enriched
Independent RCT confirming combination superiority over MTX monotherapy on patient-reported and HRQOL outcomes over 2 years.
“Patients treated with adalimumab plus MTX demonstrated significant baseline to Week 104 improvements in HAQ-DI (p < 0.0001), SF-36 Physical Component Summary (p < 0.0001), 4 SF-36 domains [physical function (p < 0.0001), bodily pain (p <0.0001), vitality (p = 0.0139), role limitations-physical (p = 0.0005)], SF-6D (p = 0.0152), VAS-PtGA (p < 0.0001), VAS-pain (p < 0.0001), FACIT-F (p < 0.0001), and HUI-3 (p = 0.0034) scores versus patients treated with MTX monotherapy.”
Panel auditInternal validity: high · scope of inference: Early RA patients, patient-reported and HRQOL outcomes of adalimumab+MTX versus MTX monotherapy.Key limitations: outcomes are HRQOL/function rather than hard clinical endpoints in this report
Places adalimumab+MTX as an active comparator against placebo+MTX in MTX-IR RA, though the quantified contrast is upadacitinib-focused.
“upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms”
Panel auditInternal validity: high · scope of inference: RA with inadequate MTX response, comparing upadacitinib against adalimumab and placebo on background MTX.Key limitations: TNFi+MTX vs placebo+MTX contrast not reported · focus on JAK comparator
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct, consistent RCT evidence supports superiority, but single-molecule coverage and partial long-term clinical convergence keep confidence in the Likely band rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Non-adalimumab TNFi head-to-head versus MTX monotherapy. The class claim rests entirely on adalimumab [4][5][6][9]; etanercept, infliximab, golimumab and certolizumab are untested against MTX monotherapy in this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Randomised controlled trials of each remaining TNF inhibitor plus MTX versus MTX monotherapy in RA with clinical, functional and radiographic endpoints.
Open question: Do TNF inhibitors other than adalimumab show the same superiority over methotrexate monotherapy in RA? Why it is still open: Every qualifying study in the corpus tests adalimumab only [4][5][6][9]; no other TNFi is compared against MTX monotherapy.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19